Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells $314,999.72 in Stock

Solid Biosciences Inc. (NASDAQ:SLDB) CEO Alexander Cumbo sold 48,913 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total transaction of $314,999.72. Following the sale, the chief executive officer directly owned 222,018 shares in the company, valued at $1,429,795.92. The trade was a 18.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Alexander Cumbo also recently made the following trade(s):

• On Monday, February 2nd, Alexander Cumbo sold 80,258 shares of Solid Biosciences stock. The stock was sold at an average price of $6.44, for a total value of $516,861.52.
• On Monday, February 2nd, Alexander Cumbo sold 80,258 shares of Solid Biosciences stock. The shares were sold at an average price of $6.44, for a total value of $516,861.52.
• On Wednesday, December 3rd, Alexander Cumbo sold 10,808 shares of Solid Biosciences stock. The stock was sold at an average price of $5.11, for a total value of $55,228.88.

Solid Biosciences Stock Up 4.7%

SLDB stock opened at $6.52 on Monday. The firm has a market capitalization of $507.97 million, a PE ratio of -2.62 and a beta of 2.67. Solid Biosciences Inc. has a twelve month low of $2.41 and a twelve month high of $7.37. The stock has a 50-day simple moving average of $5.84 and a two-hundred day simple moving average of $5.71.

Trending Headlines about Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Company will present at the Guggenheim Emerging Outlook: Biotech Summit (CEO Bo Cumbo presenting Feb 12) — this gives Solid (SLDB) direct exposure to institutional investors and can support a rally if management provides encouraging clinical, regulatory, or financing updates. Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
• Neutral Sentiment: Trading context: SLDB is trading above recent moving averages with volume notably above its average — this suggests heightened interest but does not by itself indicate direction until drivers (presentation vs. insider sales) dominate.
• Negative Sentiment: CEO Alexander (Alex) Cumbo sold 48,913 shares at an average $6.44 (≈$315k); his holding fell ~18.1% — a large CEO sale can be read negatively by investors even if for personal reasons. CEO Sale SEC Filing
• Negative Sentiment: CFO Kevin Tan sold 14,783 shares at $6.44 (~$95k); his position fell ~13.6% — another senior officer reduction that may weigh on sentiment. CFO Sale SEC Filing
• Negative Sentiment: COO David T. Howton sold 18,894 shares at $6.44 (~$122k); ownership declined ~16.2%. COO Sale SEC Filing
• Negative Sentiment: CTO Paul Herzich sold 10,905 shares at $6.44 (~$70k); holding fell ~13.6%. CTO Sale SEC Filing
• Negative Sentiment: Other insiders — director Ilan Ganot (7,205 shares), insider Jessie Hanrahan (12,348 shares), and Gabriel Brooks (12,616 shares) — each sold at $6.44, reducing holdings by double-digit percentages; collectively these sales increase supply pressure and raise investor questions about insider confidence. Director/Insider Sales SEC Filings

Wall Street Analyst Weigh In

A number of research firms have recently commented on SLDB. Needham & Company LLC restated a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Wednesday, January 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. JPMorgan Chase & Co. decreased their target price on Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Wall Street Zen cut Solid Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. Finally, Citigroup reissued a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $14.70.

Institutional Trading of Solid Biosciences

A number of hedge funds have recently bought and sold shares of the company. Vestal Point Capital LP grew its position in Solid Biosciences by 97.7% during the third quarter. Vestal Point Capital LP now owns 2,975,000 shares of the company’s stock valued at $18,356,000 after acquiring an additional 1,470,000 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Solid Biosciences by 505.4% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company’s stock valued at $8,295,000 after purchasing an additional 1,421,968 shares in the last quarter. Alyeska Investment Group L.P. grew its holdings in shares of Solid Biosciences by 2.6% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,682,805 shares of the company’s stock valued at $10,383,000 after purchasing an additional 41,984 shares during the last quarter. Franklin Resources Inc. raised its position in Solid Biosciences by 28.9% in the 2nd quarter. Franklin Resources Inc. now owns 1,599,173 shares of the company’s stock worth $7,788,000 after purchasing an additional 358,473 shares during the period. Finally, Geode Capital Management LLC raised its position in Solid Biosciences by 184.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock worth $7,356,000 after purchasing an additional 979,294 shares during the period. Institutional investors own 81.46% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.